All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Alice GottliebSteering Committee Member

Alice Gottlieb is a Clinical Professor of Dermatology at the Icahn School Of Medicine at Mount Sinai, Union Square, New York, US.She is triple-boarded in dermatology, rheumatology, and internal medicine and has a PhD in immunology From from The Rockefeller University. 

Professor Gottlieb founded the Dermatology Residency Program at Tufts Medical Center and the Dermatology Division at UMDNJ-Robert Wood Johnson Medical School. She is also the founder and president of the IDEOM (International Dermatology Outcomes Measures) group. Throughout her career, Gottlieb has focused on the pathogenesis and treatment of psoriasis and psoriatic arthritis, and was the first to publish a study that demonstrated the efficacy of TNF blockers as monotherapy in psoriasis, leading to TNF blockers being approved for use and resulting in significant changes to the way psoriasis is treated.